<DOC>
	<DOCNO>NCT01358019</DOCNO>
	<brief_summary>The primary objective study examine recommend dose subsequent phase trial ( ) , observation safety toxicity profile LY2523355 patient advance and/or metastatic cancer . The secondary objective study pharmacokinetics antitumor effect .</brief_summary>
	<brief_title>A Study LY2523355 Patients With Solid Cancer</brief_title>
	<detailed_description />
	<criteria>Histological and/or cytological evidence solid tumor A diagnosis advanced and/or metastatic solid tumor Patients refractory standard therapy proven effective therapy exist Written informed consent Appropriate bone marrow , hepatic renal function ECOG PS = &lt; 1 Have serious preexist complication Have active infection require intravenous antibiotic Have symptomatic central nervous system metastasis Have current acute chronic leukemia Have autologous allogenic hematopoietic stem cell transplantation Have active multiple cancer</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>